FLUDROCORTISONE

Prostate Neoplasm

Merck Sharp & Dohme LLCSmall moleculePhase 3Active

B

59/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 73/ 100

Competitive context

69 Active assets in the Prostate Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Docetaxel Merck Sharp & Dohme LLC	Phase 4	BBB
Degarelix Novartis Pharmaceuticals	Phase 4	BBB
Prednisone Merck Sharp & Dohme LLC	Phase 3	BBB
Leuporelin Dana-Farber Cancer Institute	Phase 4	BB
Abiraterone Qilu Pharmaceutical Co., Ltd.	Phase 3	BB

View all 50 →

Same molecule, other indications

FLUDROCORTISONE is also rated in:

congenital adrenal hyperplasiaActive

BB

Indicative · Phase 3

69 / 100

Parkinson diseaseDormant

BB

Indicative · Phase 2

64 / 100

castration-resistant prostate carcinomaActive

B

Indicative · Phase 3

59 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.